Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 222

1.

Malignant melanoma in early Parkinson's disease: the DATATOP trial.

Constantinescu R, Romer M, Kieburtz K; DATATOP Investigators of the Parkinson Study Group.

Mov Disord. 2007 Apr 15;22(5):720-2.

PMID:
17373726
2.

Malignant melanoma and levodopa in Parkinson's disease: causality or coincidence?

Fiala KH, Whetteckey J, Manyam BV.

Parkinsonism Relat Disord. 2003 Aug;9(6):321-7. Review.

PMID:
12853231
3.

Treatment with levodopa and risk for malignant melanoma.

Olsen JH, Tangerud K, Wermuth L, Frederiksen K, Friis S.

Mov Disord. 2007 Jul 15;22(9):1252-7.

PMID:
17534943
4.

Levodopa-dyskinesia incidence by age of Parkinson's disease onset.

Kumar N, Van Gerpen JA, Bower JH, Ahlskog JE.

Mov Disord. 2005 Mar;20(3):342-4.

PMID:
15580606
5.

Melanoma, Parkinson's disease and levodopa: causal or spurious link? A review of the literature.

Zanetti R, Loria D, Rosso S.

Melanoma Res. 2006 Jun;16(3):201-6. Review.

PMID:
16718266
6.

Malignant melanoma and other types of cancer preceding Parkinson disease.

Olsen JH, Friis S, Frederiksen K.

Epidemiology. 2006 Sep;17(5):582-7.

PMID:
16837822
7.
8.

Safety of long-term levodopa therapy in malignant melanoma.

Woofter MJ, Manyam BV.

Clin Neuropharmacol. 1994 Aug;17(4):315-9.

PMID:
9316678
9.

Levodopa, melanoma, and Parkinson's disease.

Weiner WJ, Singer C, Sanchez-Ramos JR, Goldenberg JN.

Neurology. 1993 Apr;43(4):674-7. Review.

PMID:
8469320
10.

Homocysteine as a predictive factor for hip fracture in elderly women with Parkinson's disease.

Sato Y, Iwamoto J, Kanoko T, Satoh K.

Am J Med. 2005 Nov;118(11):1250-5.

PMID:
16271909
11.
12.

Parkinson's disease, levodopa-use and the risk of melanoma.

Vermeij JD, Winogrodzka A, Trip J, Weber WE.

Parkinsonism Relat Disord. 2009 Sep;15(8):551-3. doi: 10.1016/j.parkreldis.2009.05.002. Epub 2009 Jun 5. Review.

PMID:
19501540
13.

Skin cancer and Parkinson's disease.

Ferreira JJ, Neutel D, Mestre T, Coelho M, Rosa MM, Rascol O, Sampaio C.

Mov Disord. 2010 Jan 30;25(2):139-48. doi: 10.1002/mds.22855. Review.

PMID:
20063399
14.

Adding a dopamine agonist to preexisting levodopa therapy vs. levodopa therapy alone in advanced Parkinson's disease: a meta analysis.

Talati R, Baker WL, Patel AA, Reinhart K, Coleman CI.

Int J Clin Pract. 2009 Apr;63(4):613-23. doi: 10.1111/j.1742-1241.2009.02027.x. Epub 2009 Feb 16.

PMID:
19222614
15.

Treatment of Parkinson's disease in Spain.

Grandas F, Kulisevsky J.

Mov Disord. 2003 Jan;18(1):87-9.

PMID:
12518304
16.

Ten-year follow-up of Parkinson's disease patients randomized to initial therapy with ropinirole or levodopa.

Hauser RA, Rascol O, Korczyn AD, Jon Stoessl A, Watts RL, Poewe W, De Deyn PP, Lang AE.

Mov Disord. 2007 Dec;22(16):2409-17.

PMID:
17894339
17.

[Melanoma while using levodopa due to Parkinson's disease--causal association unlikely].

Wobbes T, Bonenkamp JJ.

Ned Tijdschr Geneeskd. 2002 Jul 6;146(27):1286-8. Dutch.

PMID:
12138675
19.

Current controversies: levodopa in the treatment of Parkinson's disease.

Sharma JC, Vassallo M, Ross IN.

Mov Disord. 2005 May;20(5):642-3; author reply 643-4. No abstract available.

PMID:
15732129
20.

Levodopa slows progression of Parkinson's disease: external validation by clinical trial simulation.

Chan PL, Nutt JG, Holford NH.

Pharm Res. 2007 Apr;24(4):791-802. Epub 2007 Feb 17.

PMID:
17308968

Supplemental Content

Support Center